COVID-19 Impacting Patent Litigation, From Exclusivity Forfeiture To Launch Delays
Executive Summary
Pandemic poses new hurdles for Hatch-Waxman and BPCIA litigants as they navigate US FDA approval times, sponsor filing deadlines and biosimilar launch dates.
You may also be interested in...
Genentech Was Too Slow In Trying To Halt Amgen's Herceptin Biosimilar Launch
Genentech's delay in requesting an injunction, as well as its licensing deals with Mylan, Celltrion and Pfizer, show it won't suffer irreparable harm from sales of Amgen's biosimilar, judge says.
How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?
In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.